HUL is the safe FMCG bet that has gone nowhere. The question is whether FY27 finally moves it (NSE: HINDUNILVR)
Read More Healthcare Industry News Is Fulgent Genetics rebuilding itself as a pathology-first diagnostics platform after losing a major customer? Fulgent Genetics targets $350M 2026 revenue as pathology expansion reshapes its customer mix. Read how the strategy could stabilise growth. byPallavi MadhirajuMarch 1, 2026